National Comprehensive Cancer Network

About NCCN

NCCN Guidelines for Patients for Melanoma Updated

Carrie Capili, Communications Specialist

Despite recent treatment advances, melanoma remains the most serious form of skin cancer and the leading cause of death from skin disease, attributing to approximately 70,000 diagnoses each year. To provide people with melanoma and their caregivers with state-of-the-art treatment information in patient-friendly language, the National Comprehensive Cancer Network® (NCCN®) has developed an updated version of the NCCN Guidelines for Patients™: Melanoma. Included in this 2011 Version is information about vemurafenib (Zelboraf®, Genentech), a targeted therapy recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma, and ipilimumab (Yervoy™, Bristol-Myers Squibb), an immunotherapy also recently approved by the FDA for advanced melanoma.

The NCCN Guidelines for Patients are consumer-friendly translations of the professional NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), which physicians around the globe use when determining appropriate cancer treatment. The NCCN Guidelines for Patients present the same information that physicians use when making treatment decisions in an easy-to-understand format for people with cancer.

The updated NCCN Guidelines for Patients: Melanoma is available free of charge both online at and and in print booklet format. To request a hard copy of this resource, e-mail

Through the support of the NCCN Foundation, NCCN offers a library of NCCN Guidelines for Patients including those on breast, non-small cell lung, ovarian, and prostate cancers, chronic myelogenous leukemia, malignant pleural mesothelioma, and multiple myeloma. All of these Guidelines are available free of charge at, which also features informative articles for patients and caregivers. These guidelines are also featured on